P-glycoprotein-associated resistance to taxol and taxotère and its reversal by dexniguldipine-HCl, dexverapamil-HCl, or cyclosporin a

International Journal of Oncology

Volumn 8, Issue 5, 1996, Pages 951-956

  Beck, James ^a  

^a ALTANA PHARMA AG   (Germany)

Author keywords

Cyclosporin A; Dexniguldipine HCl; Dexverapamil HCl; MRP; P glycoprotein; Taxane resistance

Indexed keywords

B 8909 008; CYCLOSPORIN A; DEXNIGULDIPINE; DEXVERAPAMIL; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; M 1; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG SENSITIZATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0029938978     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Bissery MC, Guenard D, Gueritte-Voegelein F and Lavelle F: Experimental antitumor activity of taxotère (RP 56976, NSC 628 503), a taxol analogue. Cancer Res 51: 4845-4852, 1991.
2. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.